Gregory Sahagian, MD
Bruce Seligmann, PhD, Milos Babic, PhD, Kathleen Scully, PhD, Salvatore Camiolo, PhD, Joanne M Yeakley, PhD and Gregory Sahagian, MD; A Gene Expression Signature for Alzheimer’s From Finger Prick Blood Spotted on a Filter Paper Card AAIC meeting 2022 abstract
Gregory Sahagian, Yessar Hussain, Marc H. Feinberg, Ali A. Habib, Thomas Skripuletz, Tobias Ruck, Roberto Arnaboldi, Edward Brauer, Deborah Gelinas, Li Liu, Jana Podhorna, Renato Mantegazza, Continuous and Fixed-Cycle Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Study Design of ADAPT NXT Myology meeting 2022 abstract
Kelly Gwathmey, Gregory Sahagian, Yessar Hussain, Marc H. Feinberg, Ali A. Habib, Thomas Skripuletz, Tobias Ruck, Edward Brauer, Deborah Gelinas, Sihui Zhao, Anna Bogatyreva, Renato Mantegazza; A PHASE 3B OPEN-LABEL STUDY TO FURTHER INDIVIDUALIZE EFGARTIGIMOD TREATMENT OPTIONS FOR PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS MGFA Scientific Meeting 2022 abstract
Prof James F Howard Jr, MD, Vera Bril, MD, Prof Tuan Vu, MD, Chafic Karam, MD, Stojan Peric, MD, Temur Margania, MD, Prof Hiroyuki Murai, MD, Malgorzata Bilinska, MD, Roman Shakarishvili, MD, Marek Smilowski, MD, Antonio Guglietta, MD, Peter Ulrichts, PhD, Tony Vangeneugden, PhD, Kimiaki Utsugisawa, MD, Prof Jan Verschuuren, MD, Renato Mantegazza, MD, the ADAPT Investigator Study Group Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial Lancet Neurology VOLUME 20, ISSUE 7, P526-536, JULY 01, 2021
Dean Wingerchuk MD, Kazuo Fujihara MD, Jacqueline Palace DM, Achim Berthele MD, Michael Levy MD, PhD, Ho Jin Kim MD, PhD, Ichiro Nakashima MD, Celia Oreja-Guevara MD, PhD, Kai-Chen Wang MD, PhD, Larisa Miller PharmD, Shulian Shang PhD, Guido Sabatella MD, Marcus Yountz MD, FAAN, Sean J. Pittock MD, PREVENT Study Group Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD ANN NEUROL 2021;89:1088–1098
Lindsay Olson-Mack, Jessica Burley, Robin Calara, Robert Claycomb, Linda Couts, Mary A Kalafut, Jill Libby, Renee Richetts, Gregory Sahagian, Jean M Rockwell, Scripps Health, San Diego, CA Who Are We Missing? False Call Rates Decline for Stroke Code Activations During Early Phase of Covid-19 Pandemic Abstract poster ISC meeting 2021
Phillips G, Muppidi S, Sahagian G, Smith G, Huang, D, Campbell D; Conceptualization and Novel Budget Impact Analysis Framework for Treatments of Myasthenia Gravis. Abstract ISPOR 2021
Smith N, Howard J, Sahagian G, Smith G, Silvestri NJ, Hehir M, Leighton T, Jeyakumar S, Phillips GA; Comparative Effectiveness and Safety of Efgartigimod in Generalized Myasthenia Gravis Abstract ISPOR 2021
Wagner, G., Rosen, J., Vignisson, V., Sahagian, G., Haase-Alasantro, L;.A pilot study investigating a voice recognition cognitive screening tool for detection of neuropsychological changes; Abstract AAIC 2021
Wagner, G., Rosen, J., Holguin, G., Frishberg, B., Wang, A., Sahagian, G., Haase-Alasantro, (2016). Clinical Assessment of Posterior Cortical Atrophy. Poster presented at the National Academy of Neuropsychology Conference, Seattle, WA.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014 Jan 23;370(4):322-33
Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials Neurology. 2015 Aug 25;85(8):692-700
Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA: Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999 Sep 13; 159(16): 1931-7
Amy C. Almaraz Nielsen, DO
Almaraz AC, Bobrow BJ, Wingerchuk DM, Wellik KE, Demaerschalk BM. Serum neuron specific enolase to predict neurological outcome after cardiopulmonary resuscitation: a critically appraised topic. Neurologist 2009 Jan; 15(1):44-8. PMID:19131859. DOI:10.1097/NRL.0b013e318191f810.
Almaraz AC, Driver-Dunckley ED, Woodruff BK, Wellik KE, Caselli RJ, Demaerschalk BM, Adler CH, Caviness JN, Wingerchuk DM. Efficacy of rivastigmine for cognitive symptoms in Parkinson disease with dementia.
Neurologist 2009 Jul; 15(4):234-7. PMID:19590387. DOI:10.1097/NRL.0b013e3181a968df.
Hlubocky, A, M.D., Weidenbeck, TL, M.D, Mckinnon, JH M.D., Almaraz, AC, D.O., Carter, JL M.D.,Evidente, VH, M.D. Acute Combined Degeneration Associated with B12 Deficiency and Nitrous Oxide Anesthesia. Poster presentation AAN 2010, manuscript in progress
Almaraz AC, Sirven JI. Book review. Dillion WP, Binder DK, Sonne DC, Fischbein NJ, “Cranial Nerves: Anatomy, Pathology, Imaging”. Thieme Medical Publishers, inc, New York, 2010.
Almaraz A, Dilli E, Dodick D. The Effect of Prophylactic Medications on TMS for Migraine Aura. Headache Nov 2010; 50(10):1630-33.
Amy C Almaraz, Katherine Noe, David Fortuin, John Sweeney, Richard Lee, David W. Dodick. “Is There a PFO Closure Responsive Migraine Subgroup”. Headache 2010 in print
Almaraz, A DO, Bosch Peter E MD. A Case of Muscle Restricted Vasculitis. Journal of Clinical Neuromuscular
Disease March 2012;13(3):117-121.
Anchi Wang, MD
Wang, A., and Jankovic, J., Hemifacial spasm: clinical findings and treatment, Muscle and Nerve 21:1740-1747, 1998
Wang, A., Fathallah-Shaykh, H. and Rosenberg, R.N. Case 24 “Acute Vertigo and Ataxia”, pp.201-207. clinical Cases in Neurology; Edited by A.H.V. Schapira and L.P. Rowland; Butterworth-Heinemann Inc., Oxford and Buxton; 2001.
William G. Ondo, Anchi Wang, Madhavi Thomas and Kevin Dat Vuong, “Evaluating factors that can influence spirography ratings in patients with essential tremor”, Parkinsonism & Related Disorders, Volume 11, Issue 1, January 2005, Pages 45-48,
Benjamin Frishberg, MD
Kawabori M, Okonkwo DO, McAllister P, Chen JW, Frishberg BM, Achrol AK, Gross RE, Steinberg GK, Imai H, Yasuhara T, Suenaga J, Nakamura H, Karasawa Y, Hamada J, Bates D, Kaneko T. Safety and Clinical Outcomes in Traumatic Brain Injury Patients: Interim Analysis of the STEMTRA Trial.
Presented at the 14th Korea-Japan Joint Conference on Surgery for Cerebral Stroke. Sapporo, Japan; April 26-28, 2019.
Karasawa Y, Imai H, Okonkwo DO, McAllister P, Kawabori M, Chen JW, Frishberg BM, Yasuhara T, Suenaga J, Nakamura H, Bates D, Kaneko T. Safety and Clinical Outcomes in Traumatic Brain Injury Patients: Interim Analysis of the STEMTRA Trial. Presented at the 20th Annual Meeting of the Japan Society for Molecular Neurosurgery. Tokyo, Japan; August 8-9, 2019.
Okonkwo DO, McAllister P, Kawabori M, Chen JW, Frishberg BM, Achrol AK, Gross RE, Steinberg GK, Imai H, Lu D, Yasuhara T, Bates D. Safety and Clinical Outcomes following SB623 Stem Cell Implantation in Chronic Traumatic Brain Injury Patients: Interim Analysis of the Phase 2 STEMTRA
Trial. Presented at the Military Health System Research Symposium. Kissimmee, FL; August 19-22, 2019.
Steinberg GK, Okonkwo DO, Semeniv I, Zinkevych L, McAllister P, Kawabori M, Chen JW, Frishberg BM,
Achrol AK, Lai A, Gross RE, Weintraub AH, Lu D, Yasuhara T, Imai H, Paadre S, Niakian M, Kaneko T, Bates D. Safety/Efficacy of Bone Marrow-Derived Mesenchymal Stem Cells (SB623) Implantation after Chronic Traumatic Brain Injury. Presented at the American Academy of
Neurological Surgery 81st Annual Meeting. Rome, Italy; September 19, 2019.
Imai H, Kawabori M, Yasuhara T, Okonkwo DO, McAllister P, Chen JW, Frishberg BM, Achrol AK, Gross RE, Steinberg GK, Lu D, Suenaga J, Nakamura H, Bates D, Kaneko T. One-Year Safety Outcomes in
Traumatic Brain Injury Patients after Implantation of Modified BM-Derived MSCs (SB623): The STEMTRA Trial. Presented at the 78th Annual Meeting of the Japan Neurological Society. Osaka, Japan; October 9-12, 2019.
Cramer SC, Semeniv I, McAllister P, Ikeda S, Frishberg BM, Lai A, Shinoda Y, Weintraub AH, Munin MC, Schwartz NE, Bates D. Interim Analysis of the STEMTRA Trial: Safety and Dose-Dependent Benefit in Traumatic Brain Injury Patients. To be presented at the American Congress of Rehabilitation Medicine Meeting. Chicago, IL; November 6, 2019.
Steinberg GK, Okonkwo DO, Semeniv I, Zinkevych L, McAllister P, Kawabori M, Chen JW, Frishberg BM, Achrol AK, Lai A, Gross RE, Weintraub AH, Lu D, Yasuhara T, Imai H, Paadre S, Niakian M,
Kaneko T, Bates D. Safety and Efficacy of Intracerebral Implantation of Modified Bone MarrowDerived Mesenchymal Stem Cells (SB623) in Patients with Chronic Motor Deficit from Traumatic Brain Injury. To be presented at the 65th Annual Meeting of the Western Neurosurgical Society. Scottsdale, AZ; November 8-11, 2019.
Weintraub AH, Semeniv I, McAllister P, Ikeda S, Frishberg BM, Lai A, Shinoda Y, Cramer SC, Munin MC, Schwartz NE, Bates, D. Safety and Clinical Outcomes in Chronic Traumatic Brain Injury Patients:
Pre-Specified Interim Analysis of the STEMTRA Trial. To be presented at the 15th Annual Conference on Brain Injury. New Orleans, LA; February 27-29, 2020.
McAllister P, Semeniv I, Weintraub AH, Ikeda S, Frishberg BM, Lai A, Shinoda Y, Cramer SC, Munin MC, Schwartz NE, Nejadnik B, Bates D. Pre-Specified Interim Analysis of the STEMTRA Trial: Clinical
Outcomes in Chronic Traumatic Brain Injury Patients. Submitted to the Annual Meeting of the American Academy of Neurology. Toronto, Canada; April 25-May 1, 2020.
Benjamin Frishberg MD, Headache and the Eye, in Headache and Migraine Biology and Management, Ed. Seymour Diamond, pp175-188. Elsevier 2015.
Frishberg BM., Invited Editorial. “Neuroimaging in headache: Lessons not learned” Cephalalgia. 2015 Feb 23. pii: 0333102415572919. [Epub ahead of print] No abstract available.
Loder E, Weizenbaum E, Frishberg B, Silberstein S; American Headache Society Choosing Wisely Task Force. Choosing wisely in headache medicine: the American Headache Society’s list of five things physicians
and patients should question. Headache. 2013 Nov-Dec;53(10):1651-9. doi: 10.1111/head.12233. Epub 2013 Oct 29.
Review. Coding in neuro-ophthalmology. Continuum (Minneap Minn). 2014 Aug;20(4 Neuro-ophthalmology):1075-83. doi:10.1212/01.CON.0000453301.12486.47.
Friedman DI, Frishberg B. Neuro-ophthalmology and its contribution to headaches: a case-based approach. Expert Rev Neurother. 2010 Sep;10(9):1467-78. Review.
Paul Winner, Roger K. Cady, Gary E. Ruoff, MD, Benjamin M. Frishberg, MD , W James Alexander, MD, Ying Zhang, Shashidhar H. Kori, MD, and Shelly E. Lener, PharmD. Twelve-Month Tolerability and Safety of Sumatriptan/Naproxen Sodium for the Acute Treatment of Migraine. Mayo Clin Proc. 2007 Jan;82(1):61-8
Thomas L. Davis, MD, Matthew A. Brodsky, MD, Victoria A. Carter, MD, Marc DiFazio, MD,Ben Frishberg, MD, Eugene C. Lai, MD, PhD, John McGuire, MD, Douglas P. Meyer, RPh,Jill L. Ostrem, MD, Aliya I. Sarwar, MD, and Kevin White, MD., Consensus Statement on the Use of
Botulinum Neurotoxin to Treat Spasticity in Adults. P&T 31;666-682, 2006.
Stephen D. Silberstein, MD; Alexander Mauskop, MD; Benjamin M. Frishberg, MD; Stewart J. Tepper, MD; Peter McAllister, MD; Sheena K. Aurora, MD Frederick G. Freitag, DO. Predictors of Outcomes of Botulinum Toxin Type A in the Preventive Treatment of Headache, Poster
presentation at Migraine Trust Meeting, London, 2006.
Stephen D. Silberstein, MD; Alexander Mauskop, MD; Benjamin M. Frishberg, MD; Stewart J. Tepper, MD; Peter McAllister, MD; Sheena K. Aurora, MD Frederick G. Freitag, DO. Program to Assess Headache Treatmetn Strategies: An Observational Study of Botulinum Toxin Type A in the Preventive Treatmetn of Migraine. Headache. 2006; 46: 846.
Paul Winner, DO, Roger K. Cady, MD; Gary E. Ruoff, Benjamin M. Frishberg et al Long-term Safety and Tolerability of a Fixed Single-Tablet Formulation of Sumatriptan RT Technology and Naproxen Sodium in the Acute Treatment of Migraine. Headache. 2006; 46:859-860.
Ninan T. Mathew, MD,† Benjamin M. Frishberg, MD,* Marek Gawel, MB, BCh, FRCPC,‡ Ronald DeGryse, MS, MA,§ Catherine Turkel, PharmD, MBA§ Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache in Migraineurs: A Randomized, Double-Blind, Placebo-Controlled Trial. Abstract, European Federation of Neurologic Societies meeting 2005.
Michael S. McCracken, MD; Benjamin Frishberg, MD; David B. Granet, MD; and Don O. Kikkawa, MD., Treatments for Functional Disorders: Off-Label Uses of Botulinum Toxin in Cosmetic and Clinical Applications of Botulinum Toxin, ed William Lipham MD, Slack Publishing, 2004.
Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C; BOTOX CDH Study Group. Botulinum Toxin Type A (BOTOX) for the Prophylactic Treatment of Chronic Daily Headache: A
Randomized, Double-Blind, Placebo-Controlled Trial, Headache.2005 Apr;45(4):293-307.
Frishberg, BM. “Miscellaneous Tumors of Neuro-Ophthalmologic Interest, In Walsh and Hoyt’s Clinical NeuroOphthalmology 6th Edition, Ed. Miller, N, and Newman, N. Williams and Wilkens, Baltimore MD, 2004.
Frishberg, BM. A New Formulation of Dihydroergotamine (DHE) is Effective for Sustained Relief in the Acute Treatment of Migraine”, Headache 43:5, 525, Abstract F17, May 2003.
Haneline, MT, Croft AC, Frishberg BM, “Association of internal carotid artery dissection and chiropractic manipulation”. The Neurologist. Jan;9(1):35-44. 2003
Solomon, Seymour, Frishberg, Benjamin, Hu, Henry et al, “Migraine Treatment Outcomes with Rizatriptan in triptan-Naïve Patients: A Naturalistic Study. Clinical Therapeutics 23, 886-900, 2001.
Solomon, Seymour, Frishberg, Benjamin, Hu, Henry et al. , Improved Migraine Treatment Outcomes with Rizatriptan in triptan Naïve Patients, Proc of the American Headache Society, June, 2000. Headache, Supplement 2000.
McCrory DC, Simel DL, Frishberg BM, Gray RN. Evidence Report: Neuroimaging of Patients Presenting with Headache in the Primary Care Setting. Prepared by Duke University Center for Health Policy Research:
January 5,1999; Raleigh, NC.
Frishberg BM, “Neuroimaging in Presumed Primary Headache Disorders, Seminars of Neurology, 1997
Frishberg, BM, Clinical Examination of the Trigeminal Nerve. In Walsh and Hoyt’s Clinical Neuro-Ophthalmology 5th edition. Edited by N. Miller and N. Newman, Williams and Wilkens, Baltimore, 1997.
Frishberg, BM, “To Lose a Hunt”, Proc. Frank Walsh Society, March 1996
Frishberg, BM. The Utility of Neuroimaging in the Evaluation of Headache in Patients with Normal Neurological Examinations. Neurology 1994: 1191-1197.
Pearl, PL, Frishberg, BM. Migraines in Children. In: Decision Making in Pediatric Ophthalmology. Edited by CW Cibis, AC Tongue, MS Isern. Mosby Year Book, Philadelphia, 1993.
Palestine, AG, Frishberg, BM. Macular Edema in Acquired Immunodeficiency Syndrome – Related Microvasculopathy American Journal of Ophthalmology, 111:770-771, 1991
Sapin, LR, Frishberg, BM, Sherman, JL. MRI and Neuropsychological Correlates of Dementia in Binswanger’s Disease. Archives of Clinical Neuropsychology, 5:89-97, 1990
Frishberg, BM, Spector, RH. Abdominal Mass and Bilateral Orbital Masses. Proc. Frank B. Walsh Society, 1986. Frishberg, BM, Spector, RH. Neuro-Ophthalmologic Clues to Parasellar Disease. Contemporary Neurosurgery,
Vol. 7, No. 19, 1985.
Frishberg, BM, Seybold, M. Optic Atrophy Followed by a Swollen Optic Disk. Proc. Frank B. Walsh Society, 1984
Milstein, J, Frishberg, BM. The Effect of Neonatal Hypothyroidism on Immature Rat Brain Mitochondrion. Proc Am Academy of Neurology, 1974
Bilal Choudry, MD